Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

KYTX

+ Watchlist+ Portfolio

Kyverna Therapeutics, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$4.70
52-Week Range
$4.40 – $13.67
Market Cap
$283.23M
P/E (TTM)
—
EPS (TTM)
-2.75
Dividend Yield
0.00%
Advanced Metrics
Price/Book
2.10
PEG Ratio
—
Return on Equity
-110.69%
Return on Assets
-54.14%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
7.01
Debt/Equity
0.24
Total Debt
$32.45M
Free Cash Flow
$-98.95M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$145.11M

Market Snapshot

About

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company's lead product candidate utilizes chimeric antigen receptor (CAR) T-cell technology to selectively deplete B cells that drive autoimmune conditions. Kyverna's pipeline targets diseases such as lupus nephritis, myasthenia gravis, and multiple sclerosis, applying oncology-derived cell therapy approaches to autoimmune disorders.